About HTG Molecular Diagnostics
HTG Molecular Diagnostics is a company based in Tucson (United States) founded in 1997 by Bruce E Seligmann. HTG Molecular Diagnostics has raised $50.68 million across 24 funding rounds from investors including Merck, Qiagen and HHS. HTG Molecular Diagnostics operates in a competitive market with competitors including Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Unity Biotechnology, among others.
- Headquarter Tucson, United States
- Founders Bruce E Seligmann
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website htgmolecular.com
- Social LinkedIn X
- Legal Name Htg Molecular Diagnostics, Inc.
- Annual Revenue$6.37 M (USD)-28.52as on Dec 31, 2022
- Net Profit-$21.59 M (USD)-25.95as on Dec 31, 2022
- EBITDA-$19.83 M (USD)-15.8as on Dec 31, 2022
- Total Equity Funding$50.68M (USD)
in 24 rounds
- Latest Funding Round$3M (USD), Post-IPO
Jun 2020
- InvestorsMerck
& 10 more
Funding Insights of HTG Molecular Diagnostics
HTG Molecular Diagnostics has successfully raised a total of $50.68M across 24 strategic funding rounds. The most recent funding activity was a Post-IPO round of $3 million completed in June 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $50.68M
- Total Rounds 24
- Last Round Post-IPO — $3M
- First Round $3.4M
(May 2005)
- Investors Count 11
Latest 10 of 24 funding rounds of HTG Molecular Diagnostics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2020 | $3M | Post-IPO | – | – | |
| Sep 2019 | $3.46M | Post-IPO | – | – | – |
| Jan 2018 | $2.2M | Post-IPO | – | – | |
| Aug 2014 | $16M | Debt – Conventional | – | – | – |
| Feb 2014 | $7.48M | Series E | – | – | – |
| Nov 2012 | $7.56M | Series E | – | – | – |
| Aug 2011 | $306,835 | Grant | – | – | |
| Aug 2011 | $306,835 | Grant | – | – | |
| Jun 2011 | $500,000 | Series D | – | SR One | – |
| Feb 2011 | $15.7M | Series D | – | Fletcher Spaght, Novo Holdings |
11 investors in total: 11 institutional.
Investors in HTG Molecular Diagnostics
HTG Molecular Diagnostics has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Merck, Qiagen and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage investments are targeted by Alven, a venture capital firm. | – | alven.co | Paris, France | |
Venture capital investments are directed toward marketplace and SaaS companies. | – | pointnine.com | Berlin, Germany | |
A biotechnology venture capital firm investing in innovative science. | – | srone.com | - | |
US focused seed & early stage Micro VC firm | 1995 | solcap.com | Salem, United States | |
Private equity and venture capital fund focused on the healthcare sector | – | novoholdings.dk | Hellerup, Denmark | |
Accelerator firm focused on the energy, water & agriculture sectors | – | valleyventures.org | Fresno, United States | |
US focused early-stage VC firm | – | arcturusvc.com | Pasadena, United States | |
Products and reagents for molecular diagnostic assays are supplied. | 1984 | qiagen.com | Hilden, Germany | |
Management consulting and business management services are provided. | 1983 | fletcherspaght.com | Boston, United States | |
Merck is engaged in science and technology solutions globally. | 1668 | merckgroup.com | Darmstadt, Germany |
Investor details for HTG Molecular Diagnostics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of HTG Molecular Diagnostics
11 people are tracked at HTG Molecular Diagnostics (7 in leadership, 4 in team).
| Name | Role | Group |
|---|---|---|
Bruce E Seligmann | Founder | Leadership |
Alexis PUSCH (Isere et Alsace) | Director EMEA Sales HTG Molecular | Leadership |
Patrick Roche | Sr Vice President | Leadership |
Will Trent | Chief Information Officer | Leadership |
Shaun D. McMeans | SVP & CFO | Leadership |
Christina Carruthers | Vice President Target Strategy and Early Development | Leadership |
Jeff Whitty | Director of Scientific Collaborations | Leadership |
Christine Mortel Pavlick | Corporate Application Specialist | Team |
Kim Cross | Marketing Communications Specialist | Team |
Gregory Reinholz | Senior Staff Scientist, Therapeutics | Team |
Kurt Michels | Data Scientist | Team |
Complete people profiles for HTG Molecular Diagnostics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of HTG Molecular Diagnostics
HTG Molecular Diagnostics is a publicly listed company on the OTC with ticker symbol HTGMQ in USA, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date08 May 2015
- Listed onNASDAQ: HTGM
- Listed entityHTG Molecular Diagnostics, Inc.
- Exchange sectorCommercial services
- ISINUS40434H3021
- Share price$0.00 · 2026-10-08
- Market capitalisation$2.00
- Volume (last session)209
Financials of HTG Molecular Diagnostics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2022 | $6.4M | -$21.6M | -$19.8M |
| 2021 | $8.9M | -$17.1M | -$17.1M |
| 2020 | $8.6M | -$20.9M | -$18.0M |
Detailed financial statements for HTG Molecular Diagnostics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of HTG Molecular Diagnostics
4 dated milestones of HTG Molecular Diagnostics across 23 years, from founding to its latest funding, stage changes and deals.
- Founded HTG Molecular Diagnostics is founded.
- Funding First funding round of $3.4M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $3.0M.
Competitors of HTG Molecular Diagnostics
HTG Molecular Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Unity Biotechnology, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| poseida.com | 2015 | San Diego, United States | $323.78M | 259 | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies | |
| cernostics.com | 2008 | Pittsburgh, United States | $14.18M | 16 | Precision diagnostic and prognostic tests are developed by Castle Biosciences. | |
| junotherapeutics.com | 2013 | Seattle, United States | $316.67M | 520 | CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | |
| unitybiotechnology.com | 2016 | San Francisco, United States | $206M | – | Therapeutics for aging diseases are developed by targeting senescent cells. | |
| personalis.com | 2011 | Menlo Park, United States | $87.3M | 310 | Genomic sequencing and diagnosis software is provided for healthcare. | |
| unilabs.com | 2000 | Geneva, Switzerland | – | – | Diagnostic services are provided through laboratories and radiology units. | |
| celsiustx.com | 2018 | Cambridge, United States | $148M | 50 | Single-cell RNA and genomic analysis for precision therapeutics are provided. | |
| intelliatx.com | 2014 | Cambridge, United States | $85.02M | 526 | Therapeutics using CRISPR/Cas9 are developed for various diseases. |
Detailed competitors of HTG Molecular Diagnostics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of HTG Molecular Diagnostics
The website of HTG Molecular Diagnostics (htgmolecular.com) receives about 60.3K visits a month.
- Monthly visits60.3K
▲ 308.8% vs previous month
Websites whose visitors overlap most with HTG Molecular Diagnostics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| tapbit.com | 100% | 5.1M | #4,268 | View details | |
hotcoin.com | hotcoin.com | 100% | – | #26,887 | – |
| htg-express.com | 32% | – | #4,098,000 | View details | |
htgmembers.com | htgmembers.com | 28% | – | – | – |
Latest news on Htg Molecular Diagnostics
Complete news archive for HTG Molecular Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to HTG Molecular Diagnostics
10 companies that operate in the same segment as HTG Molecular Diagnostics (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about HTG Molecular Diagnostics
HTG Molecular Diagnostics was founded in 1997 and raised its 1st funding round 8 years after it was founded.
HTG Molecular Diagnostics is headquartered in Tucson, United States. It is registered at Tucson, Arizona, United States.
HTG Molecular Diagnostics is a funded company, having raised a total of $50.68M across 24 funding rounds to date. The company's 1st funding round was a Series D of $15.7M, raised on May 2005.
Annual revenue of HTG Molecular Diagnostics is $6.37M as on Dec 31, 2022.
Developer of diagnostics and targeted therapeutics across a variety of disease areas. The company is a leading provider of molecular-based technology solutions for gene expression profiling, miRNA, siRNA, and mRNA measurement for translational medicine and diagnostic applications. Their automated HTG Edge platform is designed to quickly and simultaneously profile thousands of clinically relevant molecular targets from samples a fraction of the size required by current technologies. Also offers services (VERIO Laboratory Services ) such as retrospective sample processing, pilot studies, custom assay development, disease-specific validation studies, and molecular profiling studies.
HTG Molecular Diagnostics's top competitors include Juno Therapeutics, Personalis and Poseida Therapeutics.
Yes, HTG Molecular Diagnostics is publicly traded on OTC under the ticker symbol HTGMQ.
HTG Molecular Diagnostics has 11 investors. Key investors include Merck, Qiagen, HHS, Fletcher Spaght, and Solstice Capital.